Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer (PFE), Bristol Myers Squibb (BMY)
- Julie catches up with participants of the big pharma-sponsored New York AIDS Walk.
- Videos 2008-05-21
- Forest Laboratories: Finding Ways to Bring Drugs to Market — Fast
- Pfizer may be big, but Forest Laboratories is nimble. The smaller company competes by ushering drugs through FDA red tape in record time. Giant: Pfizer Shadow Success: Forest Laboratories, Inc. Pfizer market cap: $96.56 billion;...
- Articles 2009-06-10
Additional Resources
- Pfizer Biotech Chief Signs Vow of Silence for $1.7 Million
- Corey Goodman, the guy hired to run Pfizer's "Bioinnovation Center" in San Francisco, signed an omertà-style vow upon leaving the company: He must never talk about Pfizer again, to anyone, ever, the agreement basically states. Pfizer, which had too many R&D chiefs following its decision to merge...
- Blog posts 2009-04-28
- Pfizer's Wyeth Buy Eclipses $2.3 Bill. Bextra Troubles; 19,000 Layoffs to Come
- Today's announcement that Pfizer is to acquire Wyeth for $68 million eclipsed some things that on any other day would have been headline news in themselves: a) The fact that Pfizer's earnings were down 90 percent due to a $2.3 billion settlement with the Department of Justice over its off-label...
- Blog posts 2009-01-26
- The Pfizer-Wyeth Deal Worst-Case Scenario
- UPDATE: The deal is done! Pfizer will get Wyeth for $68 billion. See BNET's look at the deal here. Meanwhile here's the pre-deal analysis: Folks are freaking out right now on CafePharma -- sample quote on the Wyeth board: "You're Pfucked!" What will the new company be...
- Blog posts 2009-01-23
- Pfizer - Neurontin: David Franklin and the private eye
- Did Pfizer, the world's largest pharmaceutical company, cross the line on the eve of last month's crucial test trial involving its controversial anti-seizure medication Neurontin?Two weeks after the trial abruptly ended with the plaintiffs agreeing to dismiss their case with prejudice, questions linger about why Pfizer sent a former CIA...
- News items 2009-08-10
- Odds May Be Against a Pfizer-Bayer Deal
- The chatter in Europe today is the rumor that Pfizer may be interested in acquiring Bayer. Bayer's stock is trading up on the news. It's an interesting prospect. Pfizer's stock is in the dumpster and won't start looking up until its pipeline starts to revive after 2011....
- Blog posts 2008-09-09
- The Pfizer-Amgen Deal Worst-Case Scenario
- Deutsche Bank analyst Barbara Ryan has again gone public with her desire to see Pfizer get off its pile of cash and make a dramatic mega-buy that would solve its pipeline hole. This time she thinks Amgen ought to be the target. BNET readers have been down this road before....
- Blog posts 2008-12-17
- How Pfizer Hid a $2.3 Bill. Bextra Settlement in Plain Sight
- BNET pointed out today that the announcement of Pfizer's acquisition of Wyeth formed a welcome distraction for Pfizer from the news that the company was also paying a $2.3 billion settlement to make the Department of Justice stop investigating the company's illegal promotion of discontinued Cox-2 painkiller Bextra. ...
- Blog posts 2009-01-26
- Pfizer to Cap Retiree Health Benefits: Out of Time? Out of Luck.
- Pfizer is to cap the amount of healthcare benefits it will pay to retired employees based on their years of service with the company, according to The Day. Any retiree who hasn't worked long enough for Pfizer or who has expensive medical bills may find Pfizer's willingness to continue covering...
- Blog posts 2009-09-21
- Pfizer's Layoff Plan Explained
- Pfizer CEO Jeff Kindler isn't resting in his reorganization of the company. But although that plan is said not to involve layoffs, no one seems to believe it. As such, Pfizer is heading into territory previously ploughed by GlaxoSmithKline, which was plagued by layoff rumors throughout the summer while the...
- Blog posts 2008-10-08
- Pfizer-Wyeth: Credit Markets Have Doubts About the Deal; Patent Cliff Problem NOT Solved
- Some housekeeping notes on the Pfizer-Wyeth merger: The patent cliff remains unfilled, the WSJ reports: ... between 2010 and 2015, the combined company's revenues will drop by $11 billion to $62 billion. Health-care analysis firm Datamonitor estimates that products accounting for 38.5% of Pfizer's 2007 sales will...
- Blog posts 2009-01-27
- Post Merger, Pfizer-Wyeth Might Be Structured Like J&J
- When Pfizer and Wyeth complete their merger, the new company might look a bit like Johnson & Johnson: a collection of relatively small units working autonomously. That scenario emerged in a chat over a cup of tea that BNET had yesterday at Pfizer's New York HQ with...
- Blog posts 2009-02-13
- Document Shows Rogue Bextra Operation Inside Pfizer
- The "information" document filed by federal prosecutors against Mary Holloway describes what appears to be a rogue sales unit inside Pfizer dedicated to selling the painkiller Bextra off-label and at unapproved doses. Holloway is believed to be a former Pfizer employee (see Peter Rost's join-the-dots conclusion) although documents in the...
- Blog posts 2009-04-06
- Reaction to Pfizer-Wyeth: Employees Despair, Plot Rebellion; Analysts Shrug; PFE Stock Down 10%
- Reaction to the Pfizer-Wyeth merger is ... mixed, to say the least. Pfizer employees think this will be Pharmacia/Warner-Lambert redux. Wall Street analysts are all over the place. Pfizer's stock has lost 10 percent of its value between the opening bell and lunchtime. Wyeth's...
- Blog posts 2009-01-26
- Pfizer - Bextra: DOJ press conference
- Justice Department Announces Largest Health Care Fraud Settlement in Its History Pfizer to Pay $2.3 Billion for Fraudulent Marketing WASHINGTON – American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay...
- News items 2009-09-02
- Why a Pfizer Takeover of Bristol-Myers Squibb Seems Unlikely
- Deutsche Bank analyst Barbara Ryan left pharma pholks with an interesting wishbone to chew on prior to Thanksgiving -- the notion that large pharma was overdue for consolidation and that Pfizer ought to consider finally merging with Bristol-Myers Squibb. It's not a new idea, of course. But is a Pfizer...
- Blog posts 2008-11-29
- The Pfizer-Shire Deal Worst-Case Scenario
- Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...
- Blog posts 2009-01-07
- A Ranbaxy Bid Would Smell Like Desperation on Pfizer
- Last last week, reports out of India suggested that Pfizer might make a hostile bid for generic-drug maker Ranbaxy Laboratories, which last week agreed to sell itself to Japan's Daiichi Sankyo for roughly $4 billion. Pfizer may or may not actually try to bust up the Daiichi-Ranbaxy...
- Blog posts 2008-06-16
- Pfizer's "No-Layoffs" Plan Results in January '09 Layoffs
- Pfizer looks to be preparing another round of mass layoffs for January. This thread on Cafe Pharma indicates January 26 is the key date. Back in October, a Pfizer spokesperson said that the reorganization of the company into three new business units would result in "no layoffs." As BNET readers...
- Blog posts 2008-12-05
- << Previous
- page 1 of 1
- Next >>
